Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Closed Access

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

389

Citations

30

References

2013

Year

Sara A. Hurvitz, Luc Dirix, Judit Kocsis, Giulia Bianchi, Janice Lu, J. Vinholes, Ellie Guardino, Chunyan Song, Barbara Tong, Vivian Ng,

Journal of Clinical Oncology

Abstract

In this randomized phase II study, first-line treatment with T-DM1 for patients with HER2-positive MBC provided a significant improvement in PFS, with a favorable safety profile, versus HT.

References

	Year	Citations

Page 1